Boston Scientific Change in contingent consideration liability decreased by 36.4% to $7.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 800.0%, from -$1.00M to $7.00M. Over 3 years (FY 2021 to FY 2025), Change in contingent consideration liability shows an upward trend with a -49.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Fluctuations indicate changes in the expected performance of acquired businesses relative to the original deal terms.
Reflects the change in the estimated fair value of liabilities owed to sellers of acquired businesses, typically based o...
Common for companies with active M&A strategies; peers will show similar adjustments based on acquisition performance.
is_blk_contingent_consideration_fair_value_adjustment| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$85.00M | -$26.00M | -$19.00M | $12.00M | $36.00M | $20.00M | $12.00M | $19.00M | $12.00M | $15.00M | $17.00M | $2.00M | -$23.00M | -$1.00M | $5.00M | -$5.00M | $11.00M | $7.00M |
| QoQ Change | — | +69.4% | +26.9% | +163.2% | +200.0% | -44.4% | -40.0% | +58.3% | -36.8% | +25.0% | +13.3% | -88.2% | <-999% | +95.7% | +600.0% | -200.0% | +320.0% | -36.4% |
| YoY Change | — | — | — | — | +142.4% | +176.9% | +0.0% | -47.2% | -40.0% | — | +41.7% | -89.5% | -291.7% | -106.7% | -70.6% | -350.0% | +147.8% | +800.0% |